Omada Health hikes 2026 outlook after 'strongest quarter ever' in Q3. Omada Health saw its "strongest quarter ever" in the third quarter of 2026, CEO and co-founder Sean Duffy told investors and analysts during a Thursday evening earnings call. "We delivered our highest quarterly revenue, gross margin progression, and our most profitable quarter to date," Duffy said. The virtual chronic care provider, which went public last June, brought in $91 million in revenue - up 34% year-over-year - and reported gross margin of 76% on a GAAP basis and 78% on a non-GAAP basis, according to Duffy. Omada reported net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025. The company also reported adjusted EBITDA of $12 million, compared to $2 million the year prior. It beat Wall Street analysts' estimates for revenue, though slightly trailed behind projections for total membership. Total members reached 1.1 million, up 36% year-over-year, with trailing 12-month revenue per total member increasing 5% year-over-year to $294, according to financial results published Thursday. Average member tenure also grew 10% compared to the year prior, to approximately two years and four months. Member retention has improved to 58%, up from 43% in Q4 of 2024, executives said. Omada Health President Wei-Li Shao said Q3 membership growth reflects "continued demand" for its cardiometabolic platform, adding that the company's diabetes and hypertension programs continued to lead growth. The company's diabetes and hypertension programs, longer member retention and lower care delivery costs are increasingly driving both growth and profitability, executives said. "Members stayed with us longer, and our ability to provide personalized care at scale reached a new level of efficiency," Shao said. The company supports diabetes, hypertension, obesity and musculoskeletal conditions - launching a GLP-1 care companion solution last November. Shao noted that Omada deepened its partnership with the Health Care Services Corporation (HCSC) last quarter to extend its prevention and hypertension programs into three additional states, which is expected to "potentially reach an additional estimated 1.5 million covered lives at launch in 2027." "On the PBM side, we have commercial relationships with the three largest PBMs in the country, which together processed an estimated 80% of prescription claims in 2025," Shao said. "Our prescribing program is in the market now at Optum. These relationships give us the broadest distribution in Omada's history for our programs." Shao, who will take over as CEO Jan. 1, also noted that artificial intelligence solutions enable care teams to have more capacity to "apply their clinical expertise" while tailoring care to each member's needs. "This quarter shows what we have built at Omada," Shao said. "Our commercial relationships give us broad reach, and our cardiometabolic programs have driven growth. Our program mix has supported longer member tenure, and our cost to serve has decreased." Chief Financial Officer Steve Cook told investors the company expects new enrollments to "moderate sequentially" in the fourth quarter, which he said is "consistent with historic seasonality." Shao also noted that a number of employers have been spending more time making GLP-1 coverage and obesity care decisions, "given the size of the commitment, the range of solutions and the importance of getting these decisions right," which has extended the selling season deeper into the fourth quarter. Omada Health's stock dropped 19% Friday following the Q3 earnings call on Thursday as investors pulled back due to concerns about the longer selling season and expected Q4 member decline clouding the company's 2027 outlook. The company is raising its full 2026 revenue and adjusted EBITDA outlook. Cook said revenue is expected to range from $344 million to $346 million, up from its previous range of $334 million to $340 million. Adjusted EBITDA is expected to be in the range of $32 million to $34 million, up from $21 million to $27 million. "Our outlook anticipates Q4 revenue below our Q3 level, reflecting the lower new enrollment and engagement activity we have historically seen during the holidays," Cook said. "We expect revenue to come primarily from continued engagement among existing members."

Omada Health (NASDAQ: OMDA) raised its 2026 outlook after record third-quarter results. Revenue rose 34% year over year to $91 million, and net income reached nearly $7 million, against a loss of about $3 million a year earlier. Adjusted EBITDA hit a record $12 million. The company now expects 2026 revenue of $344 million to $346 million, up from $334 million to $340 million, and adjusted EBITDA of $32 million to $34 million, up from $21 million to $27 million. Members grew 36% to 1.134 million, and retention improved to 58% from 43%. Non-GAAP gross margin rose to 78% from 68%. Omada expects a seasonal fourth-quarter slowdown in revenue and members. It ended the quarter with about $243 million in cash and no debt.

Omada Health to present peer-reviewed research on improving Weight Loss and Body Composition During GLP-1 treatment at World Obesity and Weight Management Congress. The oral presentation will share results from a 12-week comparative study showing that Omada GLP-1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controls. SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) - Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Management Congress (WOC 2026) in Boston showing that members of its GLP-1 Care Track lost more weight and experienced greater improvements in body composition than GLP-1 users receiving usual care. The findings were recently published in the peer-reviewed journal Diabetes, Obesity and Metabolism.[1] GLP-1 medications can produce rapid weight loss,[2] but lean mass can account for 30% or more of the weight lost.[3,4] Lean mass is critical for overall health, as losing lean mass may contribute to reductions in resting metabolic rate[5], impaired physical function and greater susceptibility to weight regain,[6] as well as an increased risk for sarcopenia,[7] frailty, and bone loss.[6,8] While exercise and resistance training are known to be effective strategies for increasing fat loss while protecting lean mass,[1] much less is known about whether virtual care programs can improve body composition outcomes for people taking GLP-1 medications. The study followed 245 adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks.[1] Of those, 151 participated in Omada's GLP-1 Care Track and 94 received usual care, which could include medication alone or other, non-Omada lifestyle programs. More than a quarter (26%) of the usual care group reported using another lifestyle or wellness program during the study.[1] After 12 weeks, compared with the usual care group, Omada members on average:[1] * Lost more weight (6.0% of starting body weight vs. 3.3%) * Reduced their body fat percentage by about twice as much (−3.3% vs. −1.6%) * Saw a larger increase in muscle mass percentage (+0.6% vs. +0.2%) * Reported greater improvements in well-being, physical functioning, and confidence in their ability to lose weight * Saw depression and anxiety symptoms drop by roughly 30%, significantly more than the usual care group The GLP-1 Care Track provides clinical support between doctor visits. Members work with a care team that includes a dedicated health coach, GLP-1-specific peer support groups, digital tools for meal logging and behavior tracking, and AI-powered nutrition support.[1] The program also includes access to an exercise specialist who provides a personalized exercise plan developed by a physical therapist. Participants measured body composition at home using bioelectrical impedance scales. "GLP-1 care is about more than how much weight you lose. It's about the quality of the weight loss, as losing too much muscle can make it harder to keep the weight off long-term," said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. "Too many people are left to manage side effects, exercise, and nutrition on their own once GLP-1 treatment starts. This study suggests that clinical support between doctor visits can help people achieve greater weight loss and better body composition, and protect their muscle mass." This study was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada's behavior change weight health programs. Omada Health's Clinical Research Scientist, Lisa A. Stanton, PhD, will present "Improving GLP-1 Weight Loss Quality with a Virtual Lifestyle Companion Program" on Tuesday, October 20, 2026, at 3:20 PM ET during the Anti-Obesity Drugs & Emerging Therapies session at WOC 2026, held October 19-21. Omada Health Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits-where health is won or lost-at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada's virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com. * Stanton LA, Naqvi JB, Devaraj SM, et al. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. Diabetes Obes Metab. 2026:1-12. doi:10.1111/dom.71152. * Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 * Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787. doi:10.1016/S2213-8587(24)00272-9 * Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14(1):63. doi:10.1007/s13668-025-00649-w * Hopkins M, Gibbons C, Blundell J. Fat-free mass and resting metabolic rate are determinants of energy intake: implications for a theory of appetite control. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220213. doi:10.1098/rstb.2022.0213 * Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-953. doi:10.1177/0148607114550189 * Scheen AJ. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations. Diabetes Metab. 2025;52(1):101708. doi:10.1016/j.diabet.2025.101708 * Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775